| Literature DB >> 36035434 |
Abstract
Purpose: We investigated the change in skin temperature of treated areas during intense pulsed light (IPL) treatment in patients who have meibomian gland dysfunction (MGD) to determine whether there is superficial telangiectatic blood vessel ablation.Entities:
Keywords: dry eye; intense pulsed light therapy; meibomian gland dysfunction; skin temperature; vessel ablation
Year: 2022 PMID: 36035434 PMCID: PMC9399455 DOI: 10.3389/fmed.2022.893940
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Figure 1IPL treatment zone, including six periocular areas on each eyelid. IPL, intense pulsed light.
Figure 2A picture of skin temperature measurement of lower lid (A) and upper lid (B) and a picture of a thermometer (Testo 925, one-channel temperature measuring instrument T/C Type K, Testo AG, Germany) (C). Skin temperature measurement site including three periocular areas of the upper and lower lids (D).
Figure 3The schedule of IPL treatment and clinical measurements. DE and MGD parameters and the OSDI were measured before the first IPL treatment and after the fourth IPL treatment. The skin temperatures were measured before every IPL treatment. IPL, intense pulsed light; DE, dry eye; MGD, meibomian gland dysfunction; OSDI, Ocular Surface Disease Index. IPL, intense pulsed light; DE, dry eye; IPL#1, first intense pulsed light treatment; IPL#2, second intense pulsed light treatment; IPL#3, third intense pulsed light treatment; IPL#4, fourth intense pulsed light treatment; MGD, meibomian gland dysfunction; OSDI, Ocular Surface Disease Index; LL, lower eyelid; UL, upper eyelid.
Changes in the skin temperature (°C) of eyelids after each intense pulsed light treatment.
|
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|
| LL | 31.89 ± 0.72 | 30.89 ± 0.63 | 30.14 ± 0.95 | 29.74 ± 0.87 | <0.001 | <0.001 | <0.001 | <0.001 | 0.001 |
| UL | 32.01 ± 0.69 | 31.13 ± 0.75 | 30.34 ± 1.07 | 29.91 ± 0.76 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Average of LL and UL | 31.95 ± 0.70 | 31.01 ± 0.70 | 30.24 ± 1.01 | 29.83 ± 0.82 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
IPL, intense pulsed light; IPL#1, first intense pulsed light treatment; IPL#2, second intense pulsed light treatment; IPL#3, third intense pulsed light treatment; IPL#4, fourth intense pulsed light treatment; LL, Lower Eyelid; UL, Upper Eyelid.
Summary of the findings obtained before and after intense pulsed light treatments.
|
|
|
| |
|---|---|---|---|
| ST | 12.97, 10.22 | 14.45, 9.99 | 0.211 |
| TBUT | 3.15, 1.38 | 5.53, 2.34 | <0.001 |
| CFS | 1.61, 3.09 | 0.50, 0.78 | 0.001 |
| LLT | 71.88, 26.34 | 68.38, 24.16 | 0.209 |
| LAS | 1.96, 0.62 | 0.86, 0.67 | <0.001 |
| ME | 1.67, 0.87 | 1.03, 1.67 | <0.001 |
| MQ | 18.18, 6.34 | 10.16, 5.48 | <0.001 |
| OSDI | 35.38, 19.97 | 15.48, 34.32 | <0.001 |
IPL#1, first intense pulsed light treatment; IPL#4, fourth intense pulsed light treatment; ST, Schirmer 1 Test; TBUT, Tear Break-Up Time; CFS, Corneal and Conjunctival Staining Scores; LLT, Lipid Layer Thickness; LAS, lid margin abnormality score; ME, Meibum Expressibility; MQ, Meibum Quality, OSDI, Ocular Surface Disease Index.
Multivariate linear regression analysis between skin temperature (°C) change and DE and MGD parameter improvement.
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||
| LAS | 0.099 | 0.287 | LAS | 0.009 | 0.939 | LAS | 0.084 | 0.476 |
| ME | −0.090 | 0.250 | ME | −0.0743 | 0.483 | ME | −0.107 | 0.284 |
| MQ | −0.132 | 0.871 | MQ | 0.567 | 0.596 | MQ | 0.158 | 0.878 |
| CFS | 0.912 | 0.009 | CFS | 0.408 | 0.040 | CFS | 0.928 | 0.040 |
| TBUT | −0.028 | 0.919 | TBUT | −0.042 | 0.908 | TBUT | −0.043 | 0.904 |
| OSDI | −0.577 | 0.696 | OSDI | 0.071 | 0.975 | OSDI | −0.514 | 0.816 |
LL, lower eyelid; UL, upper eyelid; TBUT, Tear Break-Up Time; LAS, Lid Margin Abnormality Score; ME, Meibum Expressibility; MQ, Meibum Quality; CFS, Corneal and Conjunctival Staining Scores; OSDI, Ocular Surface Disease Index.